Day One Biopharmaceuticals, Inc.·4

Apr 23, 4:33 PM ET

Dable Habib J 4

Research Summary

AI-generated summary

Updated

Day One Biopharmaceuticals (DAWN) Director Dable Habib J Sells 136,495 Shares

What Happened
Dable Habib J, a director of Day One Biopharmaceuticals, reported dispositions of derivative awards totaling 136,495 shares on April 23, 2026. These derivative awards (options/RSUs) were settled for cash as part of the merger with Servier: the merger consideration was $21.50 per share, so the disposals represent approximately $2.93 million in gross cash consideration, subject to applicable withholding taxes. This was a corporate cash-out in connection with the acquisition (not an open‑market sale).

Key Details

  • Transaction date: April 23, 2026 (effective time of the Merger). Filing date: April 23, 2026 (same day, i.e., timely per the filing).
  • Consideration: $21.50 per share (Offer Price) under the Merger Agreement; total ~ $2,934,642.50 before taxes.
  • Shares disposed: 66,660 + 32,335 + 22,500 + 15,000 = 136,495 derivative shares. Reported as dispositions to the issuer (transaction code D).
  • Nature of securities: derivative awards (stock options and/or RSUs) that were vested/accelerated and cancelled at the merger; options were converted into a cash payment equal to the Merger Consideration (or, for options, the difference between the Merger Consideration and exercise price).
  • Footnotes of note: (F2) Merger with Servier; (F3) $21.50 per share cash consideration; (F4) unvested awards were accelerated and converted to cash at closing; (F5–F9) additional vesting/RSU details.
  • Shares owned after the transaction: the filing excerpt shows these awards were cancelled/converted to cash at closing; remaining ownership of common stock after this transaction is not specified in the excerpt.
  • No 10b5-1 plan or late filing flag is indicated in the provided information.

Context
These dispositions are the typical M&A cash settlements where outstanding options and RSUs are accelerated/cancelled and converted into cash consideration — functionally a company-mandated cash-out tied to the acquisition. Such transactions reflect deal mechanics more than a director’s open-market sale decision; proceeds are net to the seller, subject to applicable tax withholdings.